EB-2 NIWBiotech and pharmaEmployerDecided March 2026Dismissed
Outcome: Dismissed
MAR122026_01B5203
Merit and national importanceNot metWell positionedNot reached / not discussedBalance favors a waiverNot reached / not discussed
Our summary
An employer petitioned for NIW for study management associate II overseeing oncology and hematology clinical trials for advanced therapies. AAO affirmed denial: while the work was meritorious, petitioner failed to show the specific endeavor had national importance or substantial economic impact beyond the employer's clients and consumers.
Official PDF
Official PDF ↗Published by USCIS. The summary is ours, in our own words; the decision text is on uscis.gov.
No criterion in the table was found met in this decision.
What was missing
- Merit and national importance · Study management associate's clinical trial work in hematologic malignancies had substantial merit but lacked demonstrated national importance at required level
Criteria
| Criterion | Reading | Why |
|---|---|---|
 Merit and national importance | Not met | Study management associate's clinical trial work in hematologic malignancies had substantial merit but lacked demonstrated national importance at required level |
 Well positioned | Not reached / not discussed | First prong failed; remaining prongs not reached per Bagamasbad |
 Balance favors a waiver | Not reached / not discussed | First prong failed; remaining prongs not reached per Bagamasbad |
A published decision describes one case. It is not legal advice and not a prediction for yours.